Table H-8. Strength of evidence for final outcome evaluations for older versus newer antiepileptic drugs under key question 1

| Outcome | Older AED | Newer AEDs | Number of Studies  (RCTs, Obs) | Design | Risk of Bias | Quality Assessment | | | Summary of Findings | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Inconsistency | Indirectness | Imprecision | Quality | Importance |
| Mortality | Carbamazepine | Gabapentin  Lamotrigine  Oxcarbazepine  Topiramate  Vigabatrin | 6 | RCTs | No serious risk of bias | Serious inconsistency | No serious indirectness | Very serious imprecision | Low | Important |
| Mortality | Phenytoin | Lamotrigine  Oxcarbazepine  Topiramate | 3 | RCTs | No serious risk of bias | Serious inconsistency | No serious indirectness | Very serious imprecision | Low | Important |
| Mortality | Valproic Acid | Lamotrigine  Topiramate  Vigabatrin | 3 | RCTs | No serious risk of bias | Serious inconsistency | No serious indirectness | Very serious imprecision | Low | Important |

AED =ntiepileptic drug; Obs =bservational study; RCT = randomized controlled trial